Loading

logo

Journal of Cellular Immunology

ISSN: 2689-2812

Commentary Open Access
Volume 5 | Issue 4 | DOI: https://doi.org/10.33696/immunology.5.176

Commentary on Updated Insight into the Role of Th2-Associated Immunity in Systemic Lupus Erythematosus

Xinyue Hou1,#, Jinjin Chu1,#, Shuhao Liu2,#, Shuyu Jin3,#, Jiamei Sun1, Hui Wang1, Haibo Li1, Wei Liu1, Chunxiang Chai4, Sue Zhang5,*, Donghua Xu1,6,*
  • 1Central Laboratory of the First Affiliated Hospital & the First Clinical College, Weifang Medical University, Weifang 261000, China
  • 2Department of Colorectal and Anal Surgery of the First Affiliated Hospital & the First Clinical College, Weifang Medical University, Weifang 261000, China
  • 3College of Pharmacology, Weifang Medical University, Weifang 261000, China
  • 4Department of Rheumatology of the Affiliated Hospital, Weifang Medical University, Weifang, 261053, China
  • 5Department of Anesthesiology, Weifang People’s Hospital, Weifang 261000, China
  • 6Department of Rheumatology of the First Affiliated Hospital & the First Clinical College, Weifang Medical University, Weifang 261000, China
  • #contributed equally to this work
+ Affiliations - Affiliations

Corresponding Author

Sue Zhang, cnwflh@sina.com; Donghua Xu, xudh@wfmc.edu.cn

Received Date: September 19, 2023

Accepted Date: October 13, 2023

Citation:

Hou X, Chu J, Liu S, Jin S, Sun J, Wang H, et al. Commentary on Updated Insight into the Role of Th2-Associated Immunity in Systemic Lupus Erythematosus. J Cell Immunol. 2023;5(4):116-119.


Copyright: © 2023 Hou X, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Abstract

Systemic lupus erythematosus (SLE) is a common autoimmune disease caused by multiple factors. The pathogenesis of SLE remains unclear. Helper T cell 2 (Th2 cell) is essential for humoral immunity, which participates in regulating type 2 immune response by producing typical cytokines of interleukin (IL)-4, IL-5, and IL-13. It is well known that Th2-associated immunity plays a vital role in autoimmune diseases, including SLE. However, current progress on the role and potential mechanism of Th2-associated immunity in SLE remains largely unknown. The work by Wang et al. have provided an in-depth association of Th2-associated immunity with SLE and the clinical application perspectives. We provide a more comprehensive and up-to-date commentary on Th2-associated immunity in regulating SLE to explore new therapeutic targets.

Keywords

Systemic lupus erythematosus, Th2-associated immunity, Cytokine, Targeted therapy

Recommended Articles

Kinetin/N6-furfuryladenine: A New Neurodegenerative Disease Lead from an Old Plant Cytokine

N6-fufuryladenine (N6FFA), or kinetin, has a long history as a plant cytokine with practical applications in agriculture. This adenosine analog is now commonplace in natural product small molecule chemical screening libraries, and as such has been discovered as active in mammalian disease pathways that include Parkinson’s disease, Huntington’s disease (HD) and Familial Dysautonomia.

Effects of a CB2 Subtype Selective Agonist ABK5-1 on Cytokine Production in Microglia

Neuroinflammation is closely associated with various diseases including neuropathic pain. Microglia are immune cells in the central nervous system which are the main players of immunity and inflammation. Since microglia are activated by nerve injury, and they produce proinflammatory mediators to cause neuropathic pain, targeting activated microglia is considered to be a strategy for treating neuropathic pain.

Cytokines (IL-1 β, IL-6, IL-18, TNF-α) in Blood and Cerebrospinal Fluid in Neonatal Hypoxia/Ischemia)

Perinatal brain injury is an important clinical and socioeconomic entity. It is a syndrome of impaired brain function in the early days of life, and it is a consequence of inadequate brain oxygenation before, during or shortly after birth, with high mortality rates and early and late morbidity rates.

Altering CAR Construct Design to Ameliorate CAR-T Cell Therapy Associated Cytokine Release Syndrome

Cytokine release syndrome represents a significant barrier to the widespread application of chimeric antigen receptor (CAR)-T cell therapies. We performed a broad analysis of preclinical and clinical studies that tested different designs of the CAR construct to tune CAR signaling, with an emphasis on effects of CAR designs on cytokine release from activated CAR-T cells. 

Efficacy of Therapeutic Plasma Exchange Alone or in Combination with Ruxolitinib for the Treatment of Penn Class 3 and 4 Cytokine Release Syndrome Complicating COVID-19

Observations early in the viral pandemic of 2020 noted the resemblance between severe coronavirus disease 2019 (COVID-19) infection and the hypercytokinemic state of secondary hemophagocytic lymphohistiocytosis (sHLH).

Full Text
Cite
Download PDF
Author Information X

About Scientific Archives

Scientific Archives is a global publisher initiated with the mission of ensuring equal opportunity for accessing science to research community all over the world. Spreading research findings with great relevance to all channels without any barrier is our goal. We want to overcome the challenges of Open Access with ensured quality and transparency.

Read More